• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
China Diabetes Market Report & Outlook For 2010-2015 Product Image

China Diabetes Market Report & Outlook For 2010-2015

  • Published: September 2010
  • Region: China
  • 89 Pages
  • IMARC Group

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

China’s diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-à-vis its present level by 2015.

“China Diabetes Market Outlook (2010-2015)” gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the READ MORE >

1. Executive Summary

2. Diabetes Disease Overview
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS

3. The Chinese Diabetes Market: Why is it so Lucrative?
3.1 CHINA HAS THE ONE OF THE LARGEST DIABETES PATIENT POOLS IN THE WORLD
3.2 CHINA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 INCREASING AFFORDABILITY OF HEALTHCARE
3.4 MORE THAN A BILLION DOLLAR WORTH OF MARKET REMAINS UNTAPPED
3.5 A BETTER IPR REGIME IS DRIVING THE LAUNCH NEW AND INNOVATIVE DRUGS

4. Drivers of Diabetes in China
4.1 AGEING POPULATION
4.2 INCREASING OBESITY LEVELS
4.3 URBANIZATION

5. The Chinese Diabetes Epidemiology
5.1 TOTAL PREVALENCE
5.1.1 Urban and Rural Prevalence
5.1.2 Prevalence of Diabetes by Sex
5.1.3 Prevalence of Diabetes by Age Group
5.2 DIAGNOSIS AND TREATMENT RATES IN CHINA

6. The Chinese Diabetes Market
6.1 MARKET TREND (2005-2009)
6.2 MARKET SEGMENTATION (2005-2009)
6.3 MARKET FORECASTS (2010-2015)

7. The Chinese Non-Insulin Anti-diabetics Market
7.1 MARKET TREND (2005-2009)
7.2 COMPETITIVE LANDSCAPE (2005-2009)
7.3 MARKET FORECASTS (2010-2015)
7.4 MARKET SEGMENTATION (2005-2015)
7.4.1 Alpha-Glycosidase Inhibitors
7.4.1.1 Market Trend (2005-2009)
7.4.1.2 Competitive Landscape
7.4.1.2.1 Share of Key Players
7.4.1.2.2 Portfolio of Key Players
7.4.1.3 Market Forecasts (2010-2015)
7.4.2 Glinides
7.4.2.1 Market Trend (2005-2009)
7.4.2.2 Competitive Landscape
7.4.2.2.1 Share of Key Players
7.4.2.2.2 Portfolio of Key Players
7.4.2.3 Market Forecasts (2010-2015)
7.4.3 Glitazones
7.4.3.1 Market Trend (2005-2009)
7.4.3.2 Competitive Landscape
7.4.3.2.1 Share of Key Players
7.4.3.2.2 Portfolio of Key Players
7.4.3.3 Market Forecasts (2010-2015)
7.4.4 Sulphonylureas
7.4.4.1 Market Trend (2005-2009)
7.4.4.2 Competitive Landscape
7.4.4.2.1 Share of Key Players
7.4.4.2.2 Portfolio of Key Players
7.4.4.3 Market Forecasts (2010-2015)
7.4.5 Biguanides
7.4.5.1 Market Trend (2005-2009)
7.4.5.2 Competitive Landscape
7.4.5.2.1 Share of Key Players
7.4.5.2.2 Portfolio of Key Players
7.4.5.3 Market Forecasts (2010-2015)
7.4.6 Dpp-IV Inhibitors
7.4.6.1 Competitive Landscape
7.4.6.1.1 Share Forecast for Key Players
7.4.6.1.2 Portfolio of Key Players
7.4.6.2 Market Forecasts (2010-2015)
7.4.7 Glp-1 Agonists
7.4.7.1 Competitive Landscape
7.4.7.1.1 Share Forecast for Key Players
7.4.7.1.2 Portfolio of Key Players
7.4.7.2 Market Forecasts (2010-2015)
7.4.8 All other Classes
7.4.8.1 Market Trend (2005-2009)
7.4.8.2 Competitive Landscape
7.4.8.2.1 Share of Key Players
7.4.8.2.2 Portfolio of Key Players
7.4.8.3 Market Forecasts (2010-2015)

8. The Chinese Insulin Market
8.1 MARKET TREND (2005-2009)
8.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
8.3 MARKET SEGMENTATION BY MODE OF ACTION
8.4 COMPETITIVE LANDSCAPE
8.4.1 Share of key Players
8.4.2 Insulin Portfolio of Key Players
8.5 MARKET FORECASTS (2005-2010)

9. Road Blocks
9.1 MILLIONS DON’T EVEN KNOW IF THEY HAVE DIABETES
9.2 DESPITE THE LARGE POPULATION BASE, AVERAGE SPENDING ON DIABETES REMAINS FAIRLY LOW
9.3 REGULATORY & BUREAUCRATIC HURDLES
9.4 LARGE FINANCIAL DISPARITY

List of Figures

Figure 2:1: The impact of Diabetes in the Human Body
Figure 2:2: Diabetes Complications
Figure 3:1: China - Personal Disposable Income (in US$ per Head), 2005-2015
Figure 3:2: China - Breakup of Consumer Expenditure (%), 2007, 2010 & 2015
Figure 3:3: China: Tapped and Untapped Diabetes Market, (in Million US$), 2010
Figure 4:1: China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (In Million), 2005, 2010, 2015, 2020, 2025
Figure 4:2 : China: Breakup of Total Population by Age Groups (0-14, 15-64 & 65-99), (in %),
Figure 4:3 : China: Diabetes Prevalence Forecast by age groups, (in %),
Figure 4:4: China: Overweight & Obese Patient Forecast, (in Million), 2005, 2010, 2015, 2020 & 2025
Figure 4:5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 4:6: China: Prevalence of Diabetes by Region (%), 2002
Figure 4:7: China: Prevalence of overweight and Obesity by Region (%), 2002
Figure 5:1: China: Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:2: China: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:3: China (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:4: China (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:5: China: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030
Figure 5:6: China (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 5:7: China (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 5:8: China: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030
Figure 5:9: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 5:10: China: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 5:11 : China: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030
Figure 5:12: China: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015
Figure 6:1: China: Diabetes Market, (in Million US$), 2005-2009
Figure 6:2: China: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:3: China: Diabetes Market, (in Million US$), 2010-2015
Figure 6:4: China: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:5: China: Contribution of Non-insulin Anti-diabetics & Insulin towards Total Growth,
Figure 7:1: China: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:2: China: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:3: China: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:4: China: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),
Figure 7:5: China: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
Figure 7:6: China: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:7: China: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %),
Figure 7:8: China: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$),
Figure 7:9: China: Glinide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:10: China: Glinide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:11: China: Glinide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:12: China: Glitazone Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:13: China: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:14: China: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:15: China: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:16: China: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),
Figure 7:17: China: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:18: China: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:19: China: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 7:20: China: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:21: China: DPP-IV Inhibitors, Value Market Share Forecast of Key Players (in %),
Figure 7:22: China: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:23: China: Glp-1 Agonist Anti-diabetics Market, Value Market Shares of Key Players
Figure 7:24: China: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 7:25: China: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 7:26: China: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players
Figure 7:27: China: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015
Figure 8:1: China: Insulin Sales, (in Million US$), 2005-2009
Figure 8:2: China: Insulin Market, Value Market Shares of Key Molecules (in %),
Figure 8:3: China: Insulin Market, Value Market Shares by Mode of Action (in %), 2009
Figure 8:4: China: Insulin Market, Value Market Shares of Key Players (in %), 2005-2009
Figure 8:5: China: Insulin Sales Forecast, (in Million US$), 2010-2015
Figure: 9:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets, 2010

List of Tables

Table 1 1: Diagnosis of Diabetes
Table 2 1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030
Table 2 2: Statistics of Top Emerging and Developed Diabetes Markets 2009
Table 2 3: Drugs Expected to be launched in the Chinese Diabetes Market, 2010-2015
Table 4 1: China: Total Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015
Table 6 1: China: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 2: China: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$),
Table 6 3: China: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),
Table 6 4: China: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$),
Table 6 5: China: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %),
Table 6 23: China: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$),
Table 6 24: China: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 25: China: Hangzhou’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 26: China: Sc.lz.Baoguang’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 27: China: Takeda’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 28: China: Jiangsu’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 35: China: Glinide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 36: China: Novo Nordisk Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 37: China: JS.L.Y.G. Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 38: China: Novartis’s Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 39: China: Js.Yangzijiang Glinide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 6: China: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 7: China: GlaxoSmithKline’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 8: China: Sichuan Taiji Ph’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 9: China: Beijing Taiyang’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 10: China: JS.L.Y.G.’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 11: China: Hangzhou’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 17: China: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 18: China: Servier Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 19: China: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 20: China: Shuanghe Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 21: China: Pfizer’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 22: China: Shanghai Fosun’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 12: China: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 13: China: Bristol-Myers Biguanide Portfolio Sales (in 000’ US$), 2005-2009
Table 6 14: China: Bj.Liling Hengtai Biguanide Portfolio Sales (in 000’ US$),
Table 6 15: China: C.T-Tianqing Biguanide Portfolio Sales (in 000’ US$),
Table 6 16: China: Guizhou Biguanide Portfolio Sales (in 000’ US$),
Table 6 29: China DPP-IV Inhibitors, Sales Forecast of Key Players (in 000’ US$), 2010 & 2015
Table 6 30: China: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2010 & 2015
Table 6 33: China: BMS /AstraZeneca DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 34: China: Boehringer Ingelheim’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 32: China: Takeda’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 31: China: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2015
Table 6 40: China: Glp-1 Agonist Anti-diabetics Market, Sales Forecast of Key Players (in 000’ US$), 2008 & 2009
Table 6 41: China: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 42: China: Novo Nordisk’s Glp-1 Agonist Portfolio Sales (in 000’ US$),
Table 6 43: China: Ipsen/Roches’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 44: China: Sanofi Aventis’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 45: China: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 46: China: Js.Nj.Hailing Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 47: China: Sh.Xiandai’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 48: China: YabaoTaiyuan All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 49: China: C.T-Tianqing All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 50: China: Shanghai Fosun All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 7 1: China: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009
Table 7 2: China: Insulin Value Shares by Molecule (in %), 2005-2009
Table 7 3: China: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009
Table 7 4: China: Insulin Value Shares by Mode of Action (in %), 2005-2009
Table 7 5: China: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 7 6: China: Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 7: China: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 8: China: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 9: China: Tonghua Dongbao’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 10: China: Bj Ganli Pharma’s Insulin Portfolio Sales (in 000’ US$), 2005-2009

- Acarbose
- Acarbose
- Actins
- Albiglutide
- Alogliptin
- Alpha-Glucosidase Inhibhitor Antidiabetics
- Amaryl
- Avandamet
- Avandia
- Basen
- Biguanide Antidiabetics
- Bydureon
- Byetta
- Diamicron
- Dpp-IV Inhibhitor Antidiabetics
- Eucreas
- Exenatide
- Exenatide
- Exenatide LAR
- Fu lai Di
- Galvus
- Glibenclami
- Glibenclamide
- Glibenclamide
- Gliciazide+Metformin
- Gliclazide
- Glieiazide+Pioglitazone
- Glimepiride
- Glimepiride+Metformin
- Glimepiride+Metformin
- Glimepiride+Pioglitazone
- Glimepiride+Pioglitazone+ Metaformin
- Glimepiride+Pioglitazone+Metaformin
- Glinide Antidiabetics
- Glipizide Pfiz
- Glipizide+Metformin
- Glipizide+Metformin
- Glipizlde
- Glitazone Antidiabetics
- Glp-1 Agonist Antidiabetics
- Glucophage
- Glurenorm
- Gymnema
- Insulin
- Janumet
- Januvia
- Ji Neng
- Ka Bo Ping
- Ka Si Ping
- Linagliptin
- Liraglutide
- Lixisenatide
- LY-2189265
- Mecobalami
- Melformin+ Rosiglitazone
- Metformin
- Metformin
- Metformin Pioglitazone
- Metformin+Nateglinide
- Metformin+Pioglitazone
- Metformin+Sitagliptin
- Metformin+Vildagliptin
- Metformin+Voglibose
- Miglitol
- Minidiab
- Nateglinide
- Nesina
- Novonorm
- Ondero
- Onglyza
- Oral-antidiabetics
- Other Drugs for Diabetes
- Ph Tang Lin
- Pioglitazone
- QiFu
- Repaglinide
- Rui Tong
- Saxagliptin
- Sitagliptin
- Starlix
- Sulpphonylurea Antidiabetics
- Tai luo
- Tang Ke Ting
- Tang Rui
- Tao Bai
- Taspoglutide
- Thioctic Acid
- Victoza
- Vildagliptin
- Voglibose
- Wan Su Ping
- Yi Fan Li

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos